Reviewing MAESTRO-NASH and the implications for hepatology and health systems in implementation/accessibility of Resmetirom
Around 5.3% of adults worldwide are living with metabolic dysfunction-associated steatohepatitis (MASH). As liver fibrosis develops, their incidence of cirrhosis, hepatocellular carcinoma, cardiovascular complications, and non-liver cancer increases. We analyse MAESTRO-NASH resmetirom data and discuss real-world implications following approval. US-based patients now have a novel treatment and expert use recommendations. We anticipate that the UK and EU will approve resmetirom; however, questions remain regarding patient selection and implementation practice.
Authors
- Scott Isaacs
- Paul Brennan (ORCID: https://orcid.org/0000-0001-8368-1478)
- Maurice Stephan Michel (ORCID: https://orcid.org/0000-0001-7424-9085)
- Naim Alkhouri (ORCID: https://orcid.org/0000-0001-9872-2391)
- Claus D. Hansen (ORCID: https://orcid.org/0000-0002-4047-2251)
- Dana Ivancovsky‐Wajcman (ORCID: https://orcid.org/0000-0002-6238-3938)
- Christopher J. Kopka (ORCID: https://orcid.org/0009-0004-7245-9184)
- Jörn M. Schattenberg (ORCID: https://orcid.org/0000-0002-4224-4703)
- Jeffrey V. Lazarus (ORCID: https://orcid.org/0000-0001-9618-2299)
- Leire Agirre‐Garrido (ORCID: https://orcid.org/0009-0003-6453-2815)
Institutions
- The Graduate Center, CUNY (US)
- Emory University (US)
- City University of New York (US)
- University of Dundee (GB)
- University of Southern Denmark (DK)
- Barcelona Institute for Global Health (ES)
- Arizona Liver Health (US)
- Saarland University (DE)
Publication Details
- Journal
- npj gut and liver.
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1038/s44355-024-00017-5
- Citations
- 15
- Primary Topic
- Clinical Nutrition and Gastroenterology
- Type
- article
- Field-Weighted Citation Impact
- 16.79
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Alexion Pharmaceuticals
- Ionis Pharmaceuticals
- Centres de Recerca de Catalunya
- Inventiva Pharma
- Intercept Pharmaceuticals
- NGM Biopharmaceuticals
- Moderna
- Generalitat de Catalunya
- Novo Nordisk
- Siemens Healthineers
- Ipsen
- Genentech
- Agencia Estatal de Investigación